- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00842439
Healthy Brains & Behavior: Understanding and Treating Youth Aggression (HBB)
Biosocial Prediction and Intervention on Childhood Aggression
Understanding the joint neurobiological and social bases to aggression is critical to future attempts to tackle this major public health problem. The overarching goals are: (a) to conduct perhaps the most systematic integration of biosocial risk factors for childhood aggression in order to predict later aggression, (b) to conduct one of the very few biosocial interventions on childhood aggression, (c) to predict and treat two fundamentally different manifestations of aggression proactive and reactive aggression which likely have different etiologies and responsiveness to treatment. The specific aims are: (1) to assess biological (genetic, neurocognitive, brain imaging, neuroendocrinological, neurotoxin, psychophysiological, nutritional), psychosocial (neighborhood, family, school, peer, psychological) and psychiatric (ADHD, CD, ODD, depression, anxiety, PTSD, schizophrenia-spectrum) risk factors for male and female aggression in order to better predict later aggression, (2) to improve prediction by identifying the genetic, neuroimaging, psychophysiological, and neuroendocrinological factors that protect children who are socially at risk for a violence outcome, (3) to develop a genetic mouse model of aggression to test the effectiveness of nutritional interventions in reducing aggression, (4) to begin to develop a new biosocial approach to the treatment and prevention of aggression, based on both cognitive-behavioral and nutrition interventions, (5) to assess the differential prediction and treatment of two fundamental variants of child aggression: proactive and reactive aggression. The human sample will consist of 500 male and female 11-year-old children drawn from high-risk communities in Philadelphia. Three hundred participants will engage in a baseline assessment for risk factors for aggression, and then be randomly assigned to one of four three-month intervention programs: treatment-as-usual, cognitive-behavioral intervention, nutrition supplementation, or CBI + nutrition. Aggression outcome will be assessed throughout intervention and post-intervention.
The investigators believe that biological risk factors will interact with social risk factors in predicting aggression, over and above main effects of these classes of risk factors. Treatment effectiveness will interact with risk factors: those with low omega-3 and high lead exposure at intake will benefit most from the nutritional intervention; those with cognitive and affective risk factors will benefit most from the neuro-cognitive-behavioral intervention.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Entry into risk assessment component:
- Must be identified by their health care provider as meeting study criteria.
- Must be 11 or 12 years old
- Can be from the general population or who exhibit problem or aggressive behavior.
- Determination if the child meets criteria for enrollment into the at-risk risk group who will be entered into the RCT will be determined by the PI at the completion of the risk assessment day.
- Participant can be of any racial or ethnic background.
- Both youth and parent must be able to speak and understand English and able to provide informed assent/consent.
Entry into intervention component:
- Entry will be determined by the findings of the risk assessment that is conducted on study entry.
- Participants diagnosed with oppositional defiant disorder or have a borderline diagnosis
- Participants diagnosed with conduct disorder or have a borderline diagnosis
- Participants who score one standard deviation above the (normed population) mean on the either the reactive or proactive components of the Reactive-Proactive Aggression questionnaire
- Participants who score one standard deviation above the mean on the aggression subscale of the CBC, will be entered into the clinical trial
- These criteria may be relaxed slightly to ensure that we have sufficient participants in the intervention phase of the study.
Exclusion Criteria:
The goal is to be inclusive rather than exclusive, so as to achieve a more naturalistic cohort of community-residing children and their parent(s). Exclusion criteria are designed to deliberately limit the sample to eliminate, to the greatest possible extent, variables that might confound our primary aims.
Exclusion criteria include:
- A diagnosed psychotic disorder
- Mental retardation
- Claustrophobia
- Currently under psychiatric care
- Pervasive developmental disorders
- Conditions that preclude participation (or increase risk) in the clinical trial (Type 1 diabetes mellitus; metabolic diseases, gastro-intestinal disorders affecting nutrient absorption, cancer)
- Currently on medication that may modify lipid metabolism
- Extensive use of nutritional supplements within the previous 3 months
- Seafood allergy
- Presence or history of orthopedic circumstances and metallic inserts interfering with MR scanning; 11) pregnant in the case of females.
- There are no exclusions by sex or race/ethnicity.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cognitive Behavioral Intervention (CBI)
Participants will meet with an interventionist once a week for 12 weeks.
They will discuss the child's behavior, will learn coping skills and how to deal with other people.
|
Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
|
Experimental: Nutritional Supplements (NUT)
Participants will be asked to take omega-3 supplements, multivitamin tablets, and calcium tablets every day for 12 weeks.
|
Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
|
Experimental: CBI + NUT
Participants will receive both the cognitive behavioral intervention and the nutritional supplements.
|
Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
|
No Intervention: No intervention
Participants will not be asked to come for sessions or any other intervention.
They will receive a list of the types of help that are available if they are interested in following up on their own.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Diagnostic interviews and questionnaires will be used to see measure changes in aggression and antisocial behavior. We will also check for levels of Omega-3 before and after the interventions to see whether there are changes in Omega-3.
Time Frame: one year
|
one year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Adrian Raine, D.Phil., University of Pennsylvania
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 808689
- SAP # 4100043366
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aggression
-
University of KonstanzCompletedAppetitive AggressionGermany
-
New York State Psychiatric InstituteCompletedIrritable AggressionUnited States
-
Boston UniversityU.S. Department of JusticeCompletedSexual Aggression | Offensive Aggression | Dating Violence Perpetration and VictimizationUnited States
-
Supernus Pharmaceuticals, Inc.CompletedImpulsive AggressionUnited States
-
Weill Medical College of Cornell UniversityGreen Chimneys Residential Treatment Center, Brewster, NYCompletedChildhood AggressionUnited States
-
University of WashingtonNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Arizona State UniversityCompletedHeavy Drinking | Sexual AggressionUnited States
-
Children's Hospital Medical Center, CincinnatiCompleted
-
Supernus Pharmaceuticals, Inc.CompletedImpulsive Aggression Comorbid With ADHDUnited Kingdom
-
Arizona State UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Georgia State UniversityNot yet recruitingAlcohol Drinking | Sexual Behavior | Emotions | Sexual AggressionUnited States
-
Arizona State UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Georgia State UniversityCompletedAlcohol Drinking | Sexual Behavior | Emotions | Sexual AggressionUnited States
Clinical Trials on CBI
-
Case Comprehensive Cancer CenterWithdrawnNon-muscle Invasive Bladder Cancer (NMIBC) | Bladder Tumor (TURBT)United States
-
Hospital Civil de GuadalajaraUniversity of GuadalajaraUnknownEnd-Stage Renal DiseaseMexico
-
VA Office of Research and DevelopmentCompleted
-
Beijing Normal UniversityCompleted
-
VA Office of Research and DevelopmentCompleted
-
Koç UniversityCompletedPsychological Distress | Well-beingTurkey
-
Johns Hopkins UniversityCompletedTobacco SmokingUnited States
-
California State University, Long BeachCompletedPhysical Inactivity
-
The University of Texas at San AntonioNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedObesity | Physical Activity | Health Knowledge, Attitudes, Practice | Healthy Eating | Gross Motor DevelopmentUnited States
-
Apollomics Inc.RecruitingGastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 SkippingUnited States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation